Shanghai Meiyue Biotech Development Co. Ltd. has identified macrocyclic compounds acting as coagulation factor XIa (FXIa) inhibitors reported to be useful for the treatment of thrombosis.

Tsinghua University has patented compounds acting as GTPase KRAS (G12D mutant)...

Impact Therapeutics (Shanghai) Inc. has presented poly(ADP-ribose) polymerase (PARP) inhibitors reported to be useful for the treatment of cancer.

Erasca Inc. has identified GTPase KRAS (Gly12Asp mutant) inhibitors reported to be useful for the treatment of cancer.

Cnpharm Co. Ltd. has described conjugates comprising docetaxel and aconitic anhydride reported to be useful for the treatment of cancer.

Biocryst Pharmaceuticals Inc. has divulged kallikrein 5 (KLK5) inhibitors reported to be useful for the treatment of Netherton syndrome.

Eleusis Therapeutics US Inc. has synthesized aryl-ring-substituted 3-phenylazetidines acting as 5-HT2 receptor ligands reported to be useful for the treatment of chronic pain, depression, atherosclerosis, chronic obstructive pulmonary disease, conjunctivitis, type 2 diabetes, multiple sclerosis and rheumatoid arthritis, among others.

Novartis AG has described novel imidazole derivatives acting as activators of the GLP-1 receptor for the treatment of obesity.

Gilead Sciences Inc. has divulged thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among others.

Medshine Discovery Inc. has identified imidazopyridine compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of autoimmune diseases.